Summary:
In 126 pregnant women with type 1 diabetes, metformin (titrated to 1000 mg twice daily) as adjunct to standard insulin therapy demonstrated significantly reduced prandial insulin requirements and modestly lower weight gain with no significant differences in glycemic control (HbA1c, time in range) compared to placebo with standard insulin therapy, with similar neonatal outcomes and no safety signals attributable to metformin, though gastrointestinal side effects were more common.
| PICO | Description |
|---|---|
| Population | 126 pregnant women with type 1 diabetes, enrolled in a multicenter randomized controlled trial. |
| Intervention | Metformin (titrated to 1000 mg twice daily) as adjunct to standard insulin therapy. |
| Comparison | Placebo with standard insulin therapy. |
| Outcome | Significantly reduced prandial insulin requirements. Modestly lower weight gain. Similar neonatal outcomes. No significant differences in HbA1c or time in range. |
Metformin in type 1 diabetes pregnancy
Double-blind RCT · T1D pregnancy · to 3rd trimester
Adjunctive metformin did not change total insulin requirement but cut the prandial insulin rise and kept gestational weight gain on target more often, with no effect on glycaemic control or neonatal outcomes.
Clinical Context
Pregnancy in type 1 diabetes requires meticulous glycemic management. Insulin requirements increase dramatically across gestation, and metformin may help address pregnancy-induced insulin resistance.
Clinical Pearls
1. Insulin-Sparing Without Glycemic Compromise: Metformin reduced insulin requirements without worsening glycemic control.
2. Prandial Rather Than Basal Effect: The reduction in prandial insulin is consistent with metformin’s mechanism of suppressing hepatic glucose production.
3. Weight Benefit Modest But Meaningful: Even small reductions in gestational weight gain may have clinical significance.
4. Reassuring Safety Profile: No increase in adverse neonatal outcomes was observed despite metformin’s placental transfer.
Practical Application
Consider metformin as adjunctive therapy in pregnant women with type 1 diabetes, particularly those experiencing rapid insulin dose escalation or excessive weight gain.
Study Limitations
Moderate sample size limits power for detecting differences in rarer outcomes. Long-term offspring outcomes weren’t reported.
Bottom Line
Adjunctive metformin in pregnant women with type 1 diabetes significantly reduces prandial insulin requirements and modestly limits weight gain without compromising glycemic control.
Source: “Metformin as Adjunct in Type 1 Diabetes Pregnancy: Multicenter Randomized Controlled Trial.” Read article